Sandbox g28: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
(22 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
<h5>Subdural empyema {{ID-returntotop-organ}}</h5> | <h5>Subdural empyema {{ID-returntotop-organ}}</h5> | ||
* Subdural empyema<ref>{{Cite journal| doi = 10.1016/S1473-3099(06)70688-0| issn = 1473-3099| volume = 7| issue = 1| pages = 62–67| last1 = Osborn| first1 = Melissa K.| last2 = Steinberg| first2 = James P.| title = Subdural empyema and other suppurative complications of paranasal sinusitis| journal = The Lancet. Infectious Diseases| date = 2007-01| pmid = 17182345}}</ref> | * Subdural empyema<ref>{{Cite journal| doi = 10.1016/S1473-3099(06)70688-0| issn = 1473-3099| volume = 7| issue = 1| pages = 62–67| last1 = Osborn| first1 = Melissa K.| last2 = Steinberg| first2 = James P.| title = Subdural empyema and other suppurative complications of paranasal sinusitis| journal = The Lancet. Infectious Diseases| date = 2007-01| pmid = 17182345}}</ref><ref>{{Cite journal| issn = 1092-8480| volume = 5| issue = 1| pages = 13–22| last = Greenlee| first = John E.| title = Subdural Empyema| journal = Current Treatment Options in Neurology| date = 2003-01| pmid = 12521560}}</ref> | ||
:* Causative pathogens | :* Causative pathogens | ||
::* More common | ::* More common | ||
Line 13: | Line 13: | ||
:::* Anaerobic Gram-positive cocci (Veillonella, Peptostreptococcus, others) | :::* Anaerobic Gram-positive cocci (Veillonella, Peptostreptococcus, others) | ||
:::* Anaerobic Gram-negative bacilli (Bacteroides, Fusobacterium, Prevotella) | :::* Anaerobic Gram-negative bacilli (Bacteroides, Fusobacterium, Prevotella) | ||
:* Empiric antimicrobial therapy | |||
:: Note (1): The choice of antimicrobial agent should be based on Gram stain results and directed against the likely causative microorganisms in the specific clinical setting. | |||
:: Note (2): Metronidazole is recommended if anaerobes are suspected. Metronidazole is not necessary for antianaerobic activity if Meropenem is used. | |||
:: Note (3): For coverage of aerobic Gram-negative bacilli, empiric therapy with Cefepime, Ceftazidime, or Meropenem is appropriate. | |||
:: Note (4): Depending on the clinical response, parenteral antimicrobial therapy should be administered for 3 to 4 weeks after drainage. Parenteral or oral therapy is frequently continued for up to a total of 6 weeks of therapy. | |||
:: Note (5): A longer course of treatment (minimum of 6–8 weeks) may be required if the patient has accompanying osteomyelitis. | |||
:: Note (6): Consider adjunctive medications including prophylactic anticonvulsants, corticosteroids, and mannitol if clinically indicated. | |||
::* '''Intracranial subdural empyema with unclear source of infection''' | |||
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h) {{and}} ([[Ceftriaxone]] 2 g IV q12h or [[Cefotaxime]] 8–12 g/day IV q4–6h) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h | |||
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present. | |||
::* '''Intracranial subdural empyema associated with sinusitis or otitis media''' | |||
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h) {{and}} ([[Ceftriaxone]] 2 g IV q12h or [[Cefotaxime]] 8–12 g/day IV q4–6h) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h | |||
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present. | |||
::* '''Intracranial subdural empyema after cranial trauma''' | |||
:::* Preferred regimen: [[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h | |||
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present. | |||
::* '''Intracranial subdural empyema after neurosurgical procedures''' | |||
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}} [[Ceftazidime]] 2 g IV q8h | |||
::* '''Intracranial subdural empyema in neonates (usually associated with meningitis)''' | |||
:::* '''Infants < 1 month''' | |||
::::* Preferred regimen: [[Ampicillin]] 200 mg/kg/day IV q4h {{and}} [[Cefotaxime]] 200 mg/kg/day IV q6h | |||
:::* '''Infants 1–3 months''' | |||
::::* Preferred regimen: [[Ampicillin]] 200 mg/kg/day IV q4h {{and}} ([[Cefotaxime]] 200 mg/kg/day IV q6h {{or}} [[Ceftriaxone]] 100 mg/kg/day IV q12h) | |||
:::* '''Infants > 3 months''' | |||
::::* Preferred regimen: [[Vancomycin]] 60 mg/kg/day IV q6h {{and}} ([[Cefotaxime]] 200 mg/kg/day IV q6h {{or}} [[Ceftriaxone]] 100 mg/kg/day IV q12h {{or}} [[Cefepime]] 150 mg/kg/day IV q8h) | |||
::* '''Spinal subdural empyema''' | |||
:::* Preferred regimen: [[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h | |||
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present. | |||
:* Pathogen-directed antimicrobial therapy | |||
::* '''Staphylococcus aureus, methicillin-resistant (MRSA)''' | |||
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h for 4–6 weeks | |||
:::* Alternative regimen: [[Linezolid]] 600 mg PO/IV q12h for 4–6 weeks {{or}} [[TMP-SMX]] 5 mg/kg/dose PO/IV q8–12h for 4–6 weeks | |||
:::* Pediatric dose: [[Vancomycin]] 15 mg/kg/dose IV q6h {{or}} [[Linezolid]] 10 mg/kg/dose PO/IV q8h | |||
:::: Note: Consider the addition of [[Rifampin]] 600 mg qd or 300–450 mg bid to vancomycin. | |||
<!--HPIM Bacterial Meningitis--><!-- | |||
:* Empiric antimicrobial therapy | :* Empiric antimicrobial therapy | ||
Line 35: | Line 81: | ||
::* '''Impaired cell-mediated immunity or hospital-acquired, post-neurosurgery, or post-traumatic meningitis (adult)''' | ::* '''Impaired cell-mediated immunity or hospital-acquired, post-neurosurgery, or post-traumatic meningitis (adult)''' | ||
:::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}} [[Vancomycin]] 2 g/day IV q12h {{and}} ([[Ceftazidime]] 6 g/day IV q8h {{or}} [[Meropenem]] 3 g/day IV q8h) | :::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}} [[Vancomycin]] 2 g/day IV q12h {{and}} ([[Ceftazidime]] 6 g/day IV q8h {{or}} [[Meropenem]] 3 g/day IV q8h) | ||
--> | |||
Latest revision as of 04:59, 8 June 2015
Subdural empyema ⇧ Return to Top ⇧
- Causative pathogens
- More common
- Streptococcus milleri
- Other streptococci and enterococci
- Aerobic Gram-negative bacilli (Haemophilus influenzae, Proteus, Escherichia coli, Pseudomonas, Klebsiella, Acinetobacter, Salmonella, Morganella, Eikenella)
- No growth
- Less common
- Streptococcus pneumoniae
- Staphylococcus aureus, coagulase-negative staphylococci
- Anaerobic Gram-positive cocci (Veillonella, Peptostreptococcus, others)
- Anaerobic Gram-negative bacilli (Bacteroides, Fusobacterium, Prevotella)
- Empiric antimicrobial therapy
- Note (1): The choice of antimicrobial agent should be based on Gram stain results and directed against the likely causative microorganisms in the specific clinical setting.
- Note (2): Metronidazole is recommended if anaerobes are suspected. Metronidazole is not necessary for antianaerobic activity if Meropenem is used.
- Note (3): For coverage of aerobic Gram-negative bacilli, empiric therapy with Cefepime, Ceftazidime, or Meropenem is appropriate.
- Note (4): Depending on the clinical response, parenteral antimicrobial therapy should be administered for 3 to 4 weeks after drainage. Parenteral or oral therapy is frequently continued for up to a total of 6 weeks of therapy.
- Note (5): A longer course of treatment (minimum of 6–8 weeks) may be required if the patient has accompanying osteomyelitis.
- Note (6): Consider adjunctive medications including prophylactic anticonvulsants, corticosteroids, and mannitol if clinically indicated.
- Intracranial subdural empyema with unclear source of infection
- Preferred regimen: (Nafcillin 2 g IV q4h or Oxacillin 2 g IV q4h) AND (Ceftriaxone 2 g IV q12h or Cefotaxime 8–12 g/day IV q4–6h) AND Metronidazole 7.5 mg/kg IV q6h
- Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
- Intracranial subdural empyema associated with sinusitis or otitis media
- Preferred regimen: (Nafcillin 2 g IV q4h or Oxacillin 2 g IV q4h) AND (Ceftriaxone 2 g IV q12h or Cefotaxime 8–12 g/day IV q4–6h) AND Metronidazole 7.5 mg/kg IV q6h
- Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
- Intracranial subdural empyema after cranial trauma
-
- Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
- Intracranial subdural empyema after neurosurgical procedures
- Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND Ceftazidime 2 g IV q8h
- Intracranial subdural empyema in neonates (usually associated with meningitis)
- Infants < 1 month
- Preferred regimen: Ampicillin 200 mg/kg/day IV q4h AND Cefotaxime 200 mg/kg/day IV q6h
- Infants 1–3 months
- Preferred regimen: Ampicillin 200 mg/kg/day IV q4h AND (Cefotaxime 200 mg/kg/day IV q6h OR Ceftriaxone 100 mg/kg/day IV q12h)
- Infants > 3 months
- Preferred regimen: Vancomycin 60 mg/kg/day IV q6h AND (Cefotaxime 200 mg/kg/day IV q6h OR Ceftriaxone 100 mg/kg/day IV q12h OR Cefepime 150 mg/kg/day IV q8h)
- Spinal subdural empyema
-
- Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
- Pathogen-directed antimicrobial therapy
- Staphylococcus aureus, methicillin-resistant (MRSA)
- Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h for 4–6 weeks
- Alternative regimen: Linezolid 600 mg PO/IV q12h for 4–6 weeks OR TMP-SMX 5 mg/kg/dose PO/IV q8–12h for 4–6 weeks
- Pediatric dose: Vancomycin 15 mg/kg/dose IV q6h OR Linezolid 10 mg/kg/dose PO/IV q8h
- Note: Consider the addition of Rifampin 600 mg qd or 300–450 mg bid to vancomycin.
- ↑ Osborn, Melissa K.; Steinberg, James P. (2007-01). "Subdural empyema and other suppurative complications of paranasal sinusitis". The Lancet. Infectious Diseases. 7 (1): 62–67. doi:10.1016/S1473-3099(06)70688-0. ISSN 1473-3099. PMID 17182345. Check date values in:
|date=
(help) - ↑ Greenlee, John E. (2003-01). "Subdural Empyema". Current Treatment Options in Neurology. 5 (1): 13–22. ISSN 1092-8480. PMID 12521560. Check date values in:
|date=
(help)